CClinicalTrials.gg
CompletedNCT06030024Updated Sep 14, 2023

Efficacy of Repetitive Transcranial Magnetic Stimulation in Adult Attention Deficit Disorder

An interventional study of repetitive Transcranial Magnetic Stimulation in Attention Deficit Disorder and ADHD, sponsored by University of Tehran. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by University of Tehran · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Sep 2021, registered Sep 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of the current open-lable study was to use low-frequency repetitive transcranial magnetic stimulation (rTMS) to improve the attention deficits in a sample of adult patients suffering from attention deficit disorder. Participants received 10 sessions of rTMS over Fz (located using the EEG 10-20 international system) and underwent assessments of their attentional capacity using the gradCPT task in an fMRI scanner, before and after the intervention. Other behavioral assessments of their attention symptoms have also been conducted.

02

Conditions studied

  • Attention Deficit Disorder
  • ADHD

Keywords

  • rTMS
  • ADHD
  • ADD
  • fMRI
03

In context

Attention Deficit Disorder with Hyperactivity

1,514 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 255 are open to participants now.

This study's enrollment of 10 is below the median of 72 across 1,207 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.

Browse Attention Deficit Disorder with Hyperactivity studies →

Lead sponsor

University of Tehran is the lead sponsor of 15 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Normal intelligence level (>90)
  • Diagnosis of ADD by a psychiatrist using the ADHD-RS-IV with Adult Prompts

Exclusion criteria

Exclusion Criteria:

  • Scores of 21 or more on BDI and/or BAI
  • History of head trauma
  • History of a major psychological or neurological condition
  • Presence of metal in the head
  • History of seizures
  • Serious cardiovascular disease
  • Use of medications with an impact on cognitive functions during the treatment window (patients with a constant and stable dose were included)
  • Recent use of alcohol or substance abuse
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Active rTMS

    Participants in this one and only arm in the current study received active repetitive transcranial magnetic stimulation.

    Device: repetitive Transcranial Magnetic Stimulation

Interventions

  • Devicerepetitive Transcranial Magnetic Stimulation

    Magnetic pulses delivered to the Fz area of the brain in a low frequency (1 Hz) manner.

06

What researchers measure

Primary outcomes

  1. Change in performance

    Shortened version (4 min) of the continuous go/no-go task: gradual-onset continuous performance task (gradCPT)

    Time frame: Up to 10 days, i.e., before and after the completion of the 10 sessions of rTMS

Secondary outcomes

  1. Change in self-report attention scores

    The 6-item ASRS-V1.1 Adult ADHD Self-Report

    Time frame: Baseline, after 5 days of stimulation, after 10 days of stimulation; Range= 0-6; Higher scores represent worse outcome

  2. Change in investigator-rated attention scores

    Investigator-Rated Attention-Deficit Hyperactivity Disorder (ADHD) Rating Scale-IV (I-ADHD RS-IV) with adult prompts

    Time frame: Baseline, after 5 days of stimulation, after 10 days of stimulation; Range:0 - 54; Higher scores represent worse outcome

07

Study locations

1 site
  • National Brain Mapping Lab
    Tehran, 1439957131, Iran, Islamic Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06030024
Lead sponsor
University of Tehran
Responsible party
reza kazemi (Assistant professor, University of Tehran) — Principal investigator
First posted
Sep 8, 2023
Start date
Sep 1, 2021
Primary completion
Feb 1, 2023
Completion
Mar 1, 2023
Last update
Sep 14, 2023

Study contacts

Reza Rostami, M.D
study director · University of Tehran
Fatemeh Soltani, MSc
principal investigator · University of Tehran

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion